High-dose omega-3 fatty acid supplementation in patients with persistent allergic rhinitis sensitized to perennial allergens: a randomized, placebo-controlled clinical trial
Abstract
Objective: To evaluate the effect of high-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the severity of allergic rhinitis and the quality of life of patients affected by this condition.
Methods: Randomized, double-blind, placebo-controlled study. Both groups received pharmacological treatment with intranasal fluticasone and allergy immunotherapy during the escalation phase. The control group received a placebo, while the experimental group received EPA capsules: 1340 mg and DHA: 924 mg daily for 2 months.
Results: The experimental group included 10 patients (2 men and 8 women), with a mean age of 31.5 ± 15.1 years, while the control group included 12 patients (5 men and 7 women) with a mean age of 27.4 ± 14.3 years (p = 0.56 for age). After the intervention, the median quality of life and nasal symptom scores were also similar between both groups (p = 0.668 and p = 0.920, respectively), with no significant differences.
Conclusion: Supplementation with high doses of EPA and DHA in patients with persistent allergic rhinitis was safe, but there was no evidence of a reduction in severity or improvement in quality of life compared to the placebo group. Further clinical trials are required to clarify its potential role as an adjunctive strategy.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 12 participants or records.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.